Hutchmed (China) (HKG:0013) has delayed the dispatch of a circular regarding the proposed disposal of a 45% stake in Shanghai Hutchison Pharmaceuticals, according to a Tuesday Hong Kong bourse filing.
The delay is due to the company requiring more time to complete certain activities under the agreement.
The parties initially entered into the contract on Dec. 31, 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.